scholarly journals Chemerin Is a Valuable Biomarker in Patients with HCV Infection and Correlates with Liver Injury

Diagnostics ◽  
2020 ◽  
Vol 10 (11) ◽  
pp. 974
Author(s):  
Georg Peschel ◽  
Jonathan Grimm ◽  
Karsten Gülow ◽  
Martina Müller ◽  
Christa Buechler ◽  
...  
Keyword(s):  
Liver Disease ◽  
Liver Fibrosis ◽  
Leukocyte Count ◽  
Hepatic Function ◽  
Meld Score ◽  
Hcv Infection ◽  
Alcoholic Fatty Liver ◽  
Advanced Liver Fibrosis ◽  
Apri Score ◽  
Progressive Liver Disease

Hepatitis C virus (HCV)-induced inflammation contributes to progressive liver disease. The chemoattractant protein chemerin is associated with systemic inflammation. We hypothesized that chemerin is a biomarker that predicts the severity of liver disease in HCV patients. Furthermore, we investigated whether serum chemerin levels change during the course of HCV treatment using direct-acting antivirals (DAAs). Therefore, we measured serum concentration of chemerin in a cohort of 82 HCV-infected patients undergoing DAA treatment. Serum chemerin was positively associated with leukocyte count and negatively with markers of hepatic function and the model of end-stage liver disease (MELD) score. Low circulating chemerin levels significantly correlated with advanced liver fibrosis and cirrhosis as measured by the fibrosis-4 (FIB-4) score, the aminotransferase/platelet (AST/PLT) ratio index (APRI) score and the non-alcoholic fatty liver disease (NAFLD) score. Chemerin did not correlate with viral load or viral genotype. Treatment with DAAs did not improve MELD score and leukocyte count within the observation period, up to three months after the end of DAA treatment. Accordingly, chemerin levels remained unchanged during the treatment period. We conclude that low circulating chemerin is a noninvasive biomarker for hepatic dysfunction and advanced liver fibrosis and cirrhosis in HCV infection.

scholarly journals Association between serum and dietary antioxidant micronutrients and advanced liver fibrosis in non-alcoholic fatty liver disease: an observational study

PeerJ ◽  
2020 ◽  
Vol 8 ◽  
pp. e9838
Author(s):  
Juliana Moraes Coelho ◽  
Katia Cansanção ◽  
Renata de Mello Perez ◽  
Nathalie Carvalho Leite ◽  
Patrícia Padilha ◽  
...  
Keyword(s):  
Liver Disease ◽  
Liver Fibrosis ◽  
Dietary Intake ◽  
Hepatic Fibrosis ◽  
Fatty Liver Disease ◽  
Advanced Fibrosis ◽  
Serum Retinol ◽  
Alcoholic Fatty Liver ◽  
Advanced Liver Fibrosis ◽  
Alcoholic Fatty Liver Disease

Background Despite clinical trials with antioxidant supplementation, few studies have been conducted to evaluate the nutritional status of antioxidant vitamins and minerals, and none have reported on the status of these serum antioxidants associated with the dietary intake of antioxidants by non-alcoholic fatty liver disease (NAFLD) patients. Objective To evaluate association between serum and dietetics antioxidants with liver fibrosis in patients with NAFLD. Methods Across-section analysis with out with 72 patients diagnosed with NAFLD. Hepatic fibrosis was measured by FibroScan®, and liver stiffness ≥7.9 kPa was considered to indicate advanced fibrosis. Retinol, alpha-tocopherol, ascorbic acid, beta-carotene, serum zinc, and selenium were evaluated, as was the dietary intake of these micronutrients in the previous 24 h (using 24-h dietary recall). The Mann–Whitney test was used to compare the fibrosis groups and, a linear regression analysis was performed to determine associated risk factors between age, sex, BMI, hepatic fibrosis, and serum antioxidants. Results A high proportion of inadequate serum retinol (20.8%), vitamin C (27%), and selenium (73.6%) was observed in the patients with NAFLD, in addition to a significant inadequacy of vitamin A (98.3%) and vitamin E (100%) intake. Patients with advanced liver fibrosis had reduced levels of serum retinol (P = 0.002), with liver fibrosis being the independent risk factor associated with serum retinol lower. Conclusion Hepatic fibrosis was associated with a reduction in serum retinol and was reduced in advanced fibrosis. NAFLD patients showed an important serum deficiency and insufficient dietary intake of the evaluated micronutrients.

scholarly journals Modelling Porcine NAFLD by Deletion of Leptin and defining the role of AMPK in hepatic fibrosis

2021 ◽  
Author(s):  
Tan Tan ◽  
Zhiyuan Song ◽  
Runming Wang ◽  
Shuheng Jiang ◽  
Zuoxiang Liang ◽  
...  
Keyword(s):  
Liver Disease ◽  
Liver Fibrosis ◽  
Fatty Liver ◽  
Hepatic Fibrosis ◽  
Alcoholic Fatty Liver ◽  
Ampk Signaling ◽  
Stat3 Phosphorylation ◽  
Advanced Liver Fibrosis ◽  
Liver Fibrogenesis

Liver fibrosis occurs during chronic liver disease. Advanced liver fibrosis results in cirrhosis, liver failure and often requires liver transplantation. However, due to the lack of human models, mechanisms underlining the pathogenesis of liver fibrosis remain unclear. Recent studies implicated a central role of deranged lipid metabolism in its pathogenesis. In this study, we generated LEPTIN deficient LEPTIN --//--) pigs using zinc finger nuclease technology to investigate the mechanisms of liver fibrosis associated with obesity . The LEPTIN pigs showed increased body fat and significant insulin resistance by 12 months of age . To resemble non alcoholic fatty liver disease (NAFLD) patients , LEPTIN pig developed the phenotypic features of fatty liver, non alcoholic steatohepatitis ( and hepatic fibrosis with age. Mean while, LEPTIN absence reduced phosphorylation of JAK2 STAT3 and AMPK. The alteration of JAK2 STAT3 enhanced fatty acid β oxidation, whereas inactivation of AMPK le d to mitochondrial autophagy, and both contributed to increased oxidative 2stress in hepatocytes . Although Leptin deletion in the rat liver altered JAK2 STAT3 phosphorylation, it activated the AMPK pathway and prevented liver fibrogenesis i n contrast with the LEPTIN pig. To our knowledge, the LEPTIN pig provides the first model recapitulating the full pathogenesis of NAFLD and its progression toward liver fibrosis . The activity of AMPK signaling pathway suggests a potential target for development of new strategies for the diagnosis and treatment of NAFLD.

HOMA-IR: An independent predictor of advanced liver fibrosis in nondiabetic non-alcoholic fatty liver disease

2019 ◽  
Vol 34 (8) ◽  
pp. 1390-1395 ◽  
Author(s):  
Hideki Fujii ◽  
Kento Imajo ◽  
Masato Yoneda ◽  
Takashi Nakahara ◽  
Hideyuki Hyogo ◽  
...  
Keyword(s):  
Liver Disease ◽  
Liver Fibrosis ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Independent Predictor ◽  
Alcoholic Fatty Liver ◽  
Advanced Liver Fibrosis ◽  
Alcoholic Fatty Liver Disease
Sign in / Sign up

Export Citation Format

Share Document